Inhibition of type-5 phosphodiesterase: Promising therapy for pulmonary hypertension

Internal Medicine

Volumn 43, Issue 10, 2004, Pages 891-893

  Watanabe, Hiroshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

cGMP; PDE 5; Pulmonary hypertension; Sildenafil

Indexed keywords

ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; ILOPROST; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; VASODILATOR AGENT;

CATHETER INFECTION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; EDITORIAL; ERECTILE DYSFUNCTION; EXERCISE TOLERANCE; HEART CATHETERIZATION; HUMAN; LUNG HEMODYNAMICS; NONHUMAN; PULMONARY HYPERTENSION; QUALITY OF LIFE; SURVIVAL TIME; TACHYPHYLAXIS;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANTIHYPERTENSIVE AGENTS; CYCLIC GMP; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES;

EID: 8844252999     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.891     Document Type: Editorial

References (18)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 336 111-117, 1997.
2. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 361: 1533-1544, 2003.
3. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76-81, 1992.
4. Roberts JD Jr, Fineman JR, Morin FC 3rd, et al, and the Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 336: 605-610, 1997.
5. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121: 409-415, 1994.
6. Lue TF. Erectile dysfunction. N Engl J Med 342: 1802-1813, 2000.
7. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 266: L536-543, 1994.
8. Lodato RF. Viagra for impotence of pulmonary vasodilator therapy? Am J Respir Crit Care Med 163: 312-313, 2001.
9. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92: 1702-1712, 2000.
10. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91: 307-310, 1999.
11. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 343: 1342, 2000.
12. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104: 424-428, 2001.
13. Watanabe H, Ohashi K, Takeuchi K, et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71 398-402, 2002.
14. Kataoka M, Satoh T, Manabe T, et al. Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol. Intern Med 43: 945-950, 2004.
15. Miggin SM, Kinsella BT. Investigation of the mechanisms of G protein: effector coupling by the human and mouse prostacyclin receptors. J Biol Chem 277: 27053-27064, 2002.
16. Murthy KS, Zhou H, Makhlouf GM. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle. Am J Physiol Cell Physiol 282: C508-517, 2002.
17. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37: 671-681, 1990.
18. Wilkens H, Guth A, König J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104: 1218-1222, 2001.